Arbutus Biopharma Corp
NASDAQ:ABUS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.88
4.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Arbutus Biopharma Corp
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
Cash Position: Arbutus ended Q3 2024 with $131 million in cash and investments, projecting its current funds will last into Q4 2026 without assuming additional capital raising.
HBV Program Progress: Positive Phase IIa data for imdusiran in combination with interferon showed up to 33% of all patients, and 67% of those with low initial surface antigen, achieved and sustained antigen loss, a leading result in the field.
Upcoming Data: The company anticipates presenting new data from its IM-PROVE I and IM-PROVE II trials at the upcoming AASLD Liver Meeting, including results from the nivolumab (anti-PD-1) combination arm.
AB-101 Advancement: The oral PD-L1 inhibitor AB-101 showed strong safety and target engagement in healthy volunteers, and is now being tested in HBV patients with initial data expected in the first half of 2025.
Litigation Updates: Key legal milestones are set, with the Moderna trial scheduled for September 2025 and a claim construction hearing in the Pfizer/BioNTech case slated for December 2024.
Functional Cure Goal: Management reiterated a 20% functional cure rate as a meaningful benchmark for new HBV therapies and is designing future trials to target and possibly exceed this threshold.
